Pfizer Stock News

Pfizer: A Strong Buy Trading Below A 10 P/E Ratio

Pfizer's stock is still reeling from the decline of its coronavirus-related sales. At least one Wall Street analyst thinks that it has a bright future.

Dividend Harvesting Portfolio Week 157: $15,700 Allocated, $1,389.49 In Projected Dividends

If you're searching for must-have stocks for wealth, look no further. In investing, identifying the right stocks leads to a fear of missing out.

The stock market keeps hitting new record highs almost every week. With sectors like semiconductors and AI taking off, the sky is the limit.

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's 'Halftime Report' to explain why he believes Pfizer is one of the best opportunities in the market right now.

Pfizer Inc. (NYSE:PFE ) TD Cowen 44th Annual Health Care Conference March 4, 2024 11:10 AM ET Company Participants David Denton - Chief Financial Officer and Executive Vice President Conference Call P

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The market valuation has become lofty, boosted by 2021-like buying behavior and a surge in growth/tech stocks. In this environment, value stocks have become very attractive, potentially allowing inves

This stock has plunged in recent years mainly because of declining demand for two of its key products. However, it's poised to return to growth, is dirt cheap, and pays an especially juicy dividend.

The S&P 500 has been trending higher by 7% in the first two months of 2024. While sentiments seem positive, the markets need to navigate blowing macroeconomic headwinds.

The fading interest in combating COVID-19 has taken a toll on Pfizer's top and bottom lines. Pfizer stock has risen and fallen with its coronavirus business, but the pullback has been exaggerated.

The fourth quarter (Q4) shined bright for hedge funds, marking it a standout period in the investment realm. According to a recent report released by a U.K.-based data investment business, global hedg

The U.S. stock market started the year with an unusual divergence, suggesting overhyped stocks. The S&P 500 hit an all-time high level at 7.3% year-to-date (YTD) rise.

Pfizer on Thursday said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its ability to protect against the illness through a second year of respiratory disease se